Findings support the value of tumour rebiopsy in NSCLC patients

New findings were presented at European Multidisciplinary Conference in Thoracic Oncology (EMCTO), held 9-11 May, 2013 in Lugano, Switzerland that detailed the mutations acquired during TKI (tyrosine kinase inhibitor) treatment in a retrospective cohort of patients with NSCLC. These findings support rebiopsy as a valuable tool for directing treatment in these patients. Read more here.